Clinical stage biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP), a specialist in antibiotics for challenging bacterial infections, on Monday announced the presentation of Phase 2 clinical trial results for ibezapolstat (IBZ) in Clostridioides difficile Infection (CDI).

The findings, presented at the 17th Biennial Congress of the Anaerobe Society of the Americas, highlighted favorable changes in gut microbiome, including increased Actinobacteria levels in IBZ-treated patients.

Dr Taryn A. Eubank from the University of Houston College of Pharmacy presented the results, affirming IBZ's clinical efficacy in treating CDI. The company plans to advance IBZ into international Phase 3 trials following successful FDA End-of-Phase 2 discussions and Phase 3 readiness. The trials will assess IBZ's clinical cure and potential to reduce CDI recurrence.

Acurx Pharmaceuticals focuses on developing novel antibiotics targeting Gram-positive bacteria, addressing critical unmet needs in infectious diseases.